Filing Flows › ADC Therapeutics SA (ADCT) › Q3 2026
ADC Therapeutics SA (ADCT) Q3 2026 earnings results (third quarter 2026)
8-K filed Nov 9, 2026
ADC Therapeutics SA (ADCT) reported revenue of $21.7M for the third quarter 2026 (Q3 2026), +32% from a year earlier and +13% from the quarter before. Operating margin was -66.1%, net loss $25.3M (116.5% of revenue).
ADC Therapeutics SA, Q3 2026: revenue $21.7M (+32% year over year), operating margin -66.1%, net loss $25.3M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $21.7M | +13% | +32% |
| Operating profit | −$14.3M | — | — |
| Net earnings | −$25.3M | — | — |
What changed
Revenue was $21.7M in Q3 2026, up 32% year over year and up 13% from the previous quarter. Product revenues, net was the largest line at 97% of revenue. Product revenues, net added $5.3M year over year (up 33%), 99% of the total change.
Operating costs exceeded revenue by $14.3M, an operating margin of -66.1%. Total costs fell 24% while revenue rose 32%. The fastest-growing cost line was General & admin (+29%). The quarter ended with a net loss of $25.3M, wider than the previous quarter's $16.6M loss.
Questions
What was ADC Therapeutics SA's revenue in the third quarter 2026?
ADC Therapeutics SA (ADCT) reported revenue of $21.7M for the third quarter 2026 (Q3 2026), +32% from a year earlier and +13% from the quarter before.
Was ADC Therapeutics SA profitable in the third quarter 2026?
Operating loss was $14.3M (-66.1% of revenue) and net loss $25.3M.
Source: ADC Therapeutics SA 8-K on SEC EDGAR.